loading page

Baseline hyper-eosinophilia: A possible predictor of hyper-progression in a patient with metastatic lung adenocarcinoma treated with pembrolizumab
  • +2
  • Salwa Koubaissi,
  • HIsham Wehbe,
  • Maria Alkozah,
  • Arafat Tfayli,
  • Jihane Faress
Salwa Koubaissi
Author Profile
HIsham Wehbe
American University of Beirut Medical Center
Author Profile
Maria Alkozah
American University of Beirut Medical Center
Author Profile
Arafat Tfayli
American University of Beirut Medical Center
Author Profile
Jihane Faress
American University of Beirut Medical Center
Author Profile

Abstract

Immune Checkpoint Inhibitors (ICI) were shown to improve survival in patients with advanced non-small cell lung cancer. Nevertheless, around 10% of treated patients may have an atypical response with disastrous tumor growth and earlier death. Readily available predictors of such response are still unrevealed and desperately needed.

Peer review status:UNDER REVIEW

30 May 2020Submitted to Clinical Case Reports
02 Jun 2020Assigned to Editor
02 Jun 2020Submission Checks Completed
10 Jun 2020Reviewer(s) Assigned